Core Insights - Bavarian Nordic A/S has entered into an agreement with Eurofarma for exclusive rights to sell and distribute its chikungunya vaccine, CHIKV VLP, in Brazil, with potential expansion to the rest of Latin America [1][8] - The agreement is based on transfer price and royalty, with Eurofarma responsible for regulatory approval and distribution costs, while Bavarian Nordic will manufacture the vaccine [2][5] - Regulatory submission to the Brazilian Health Regulatory Agency, Anvisa, is anticipated in the first half of 2026, aiming for a vaccine launch in Brazil by the second half of 2027 [3][4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines, and has a strong portfolio of travel vaccines [9] - Eurofarma, founded in 1972, is a leading Brazilian pharmaceutical company with operations in 24 countries and a significant presence in Latin America, having produced 600 million units in 2024 and achieving net revenue exceeding USD 1.78 billion [10] Vaccine Details - CHIKV VLP is a single-dose, prefilled, adjuvanted VLP recombinant protein vaccine designed for individuals aged 12 and older, with protective immunity developing as early as one week post-vaccination [5][6] - The vaccine is non-infectious, containing no viral genetic material, making it safe for a broad range of individuals [6] Disease Context - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, with Brazil accounting for more than half of the nearly 500,000 reported cases and over 200 deaths worldwide in 2025 [7] - The disease often presents with severe symptoms, and a significant percentage of patients may develop chronic symptoms lasting months or years [7]